0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Treatment of Rheumatoid Arthritis with Gammalinolenic Acid

Lawrence J. Leventhal, MD; Eric G. Boyce, PharmD; and Robert B. Zurier, MD
[+] Article and Author Information

From the University of Pennsylvania, The Graduate Hospital, Presbyterian Medical Center, and the Philadelphia College of Pharmacy and Science, Philadelphia, Pennsylvania; the University of Massachusetts Medical Center, Worcester, Massachusetts. Requests for Reprints: Robert B. Zurier, MD, Division of Rheumatology, University of Massachusetts Medical Center, 55 Lake Avenue North, Worcester, MA 01655. Acknowledgments: The authors thank Drs. Peter Callegari, Bruce Freundlich, and Joan vonFeldt for assisting in patient enrollment and Mrs. Carol Mader for preparation of the manuscript. Grant Support: National Institutes of Health grant RO1-38501, grant SP57945 from the Commonwealth of Pennsylvania, and Food and Drug Administration grant FD-R000756.


Copyright 2004 by the American College of Physicians


Ann Intern Med. 1993;119(9):867-873. doi:10.7326/0003-4819-119-9-199311010-00001
Text Size: A A A

Objective: To assess the clinical efficacy and side effects of gammalinolenic acid, a plant-seed-derived essential fatty acid that suppresses inflammation and joint tissue injury in animal models.

Design: A randomized, double-blind, placebo-controlled, 24-week trial.

Setting: Rheumatology clinic of a university hospital.

Patients: Thirty-seven patients with rheumatoid arthritis and active synovitis.

Intervention: Treatment with 1.4 g/d gammalinolenic acid in borage seed oil or cotton seed oil (placebo).

Measurements: Physicians' and patients' global assessment of disease activity; joint tenderness, joint swelling, morning stiffness, grip strength, and ability to do daily activities.

Results: Treatment with gammalinolenic acid resulted in clinically important reduction in the signs and symptoms of disease activity in patients with rheumatoid arthritis (P < 0.05). In contrast, patients given a placebo showed no change or showed worsening of disease. Gammalinolenic acid reduced the number of tender joints by 36%, the tender joint score by 45%, swollen joint count by 28%, and the swollen joint score by 41%, whereas the placebo group did not show significant improvement in any measure. Overall clinical responses (significant change in four measures) were also better in the treatment group (P < 0.05). No patients withdrew from gammalinolenic acid treatment because of adverse reactions.

Conclusion: Gammalinolenic acid in doses used in this study is a well-tolerated and effective treatment for active rheumatoid arthritis. Gammalinolenic acid is available worldwide as a component of evening primrose and borage seed oils. It is usually taken in far lower doses than used in this trial. It is not approved in the United States for the treatment of any condition and should not be viewed as therapy for any disease. Further controlled studies of its use in rheumatoid arthritis are warranted.

Figures

Grahic Jump Location
Figure 1.
Metabolic pathway of omega-6 (n-6) fatty acids.33441111

The pathway is one of progressive desaturation alternating with elongation (addition of two carbons). 18:2 = 18 carbons, 2 double bonds; (150H) DGLA = 15 hydroxy dihomogamma linolenic acid; LTC = leukotriene C ; LTB = leukotriene B ; PGE = prostaglandin E ; TXA = thromboxane A .

Grahic Jump Location
Grahic Jump Location
Figure 2.
Joint tenderness scores in patients completing the study.nn

Mean percentage change from baseline at each evaluation for placebo (open squares; = 13) and gammalinolenic acid (GLA) treatment (closed squares; = 14) groups. Error bars are 1 standard error of the mean.

Grahic Jump Location
Grahic Jump Location
Figure 3.
Joint swelling scores in patients completing the study.nn

Mean percentage change from baseline at each evaluation for placebo (open squares; = 13) and gammalinolenic acid (GLA) treatment (closed squares; = 14) groups. Error bars are 1 standard error of the mean.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)